Jabil Healthcare Launches Qfinity™ Autoinjector Platform

The Qfinity autoinjector platform provides a sustainable with a connected option for use in both clinical trial development and commercial supply.

Jabil

Jabil Healthcare, a division of Jabil, has launched the Qfinity™ autoinjector platform, a simple, reusable, modular solution for subcutaneous (SC) drug self-administration of a variety of injectables, including larger-volume, higher-viscosity medicines—supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical industry.

“The Qfinity autoinjector platform is versatile with broad technical specifications for drug volumes and drug viscosities. It features a patient-centric form factor at up to 65% lower cost per injection than market-leading disposable autoinjectors,” said Oliver Eden, Business Unit Director, Jabil Healthcare. “Our product platform is intentionally designed to be sustainable and reusable at the core, all while being delivered at a lower cost than market alternatives.”

The durable Qfinity autoinjector handles over 100 injections per device and accommodates 1 mL or 2.25 mL pre-filled disposable cassettes. Due largely to the fact that fewer components and material are consumed, it is estimated that the Qfinity autoinjector platform delivers up to a 60% reduction in carbon footprint per injection, 50% smaller manufacturing footprint, and 70% reduction in CAPEX. 

The handheld device is also available in a connected version, the Qfinity+ autoinjector, which enables medical teams to remotely monitor their patients’ care and compliance via built-in sensors and electronics—without any added complexity. The drive unit form factor and the user steps are the same as the non-connected version. The Qfinity+ Home Hub solution provides charging and seamless cellular data transfer functionality in near real-time without requiring input from the patient.

“The Qfinity+ autoinjector enables connectivity without impacting ease of use. Within the disposable mechanical autoinjector market, a common route for delivering connectivity is a ‘sleeve’ that fits over the autoinjector and captures adherence and/or compliance and communicates those events to the user’s smartphone via Bluetooth. Jabil’s decision to instead develop the cellular Qfinity+ Home Hub solution goes back to our primary objective: maximizing access,” said Conor Mulcahy, Senior Director of Strategic Projects, Jabil.


Companies in this article
More in Medical device/Packaging